The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In an expansion move within the biotech sector, Zymeworks announced the acquisition of Theravance Biopharma for approximately $929 million in equity, a deal that includes the YUPELRI product for chronic obstructive pulmonary disease. Following the announcement, B. Riley reiterated its buy rating on the stock with a $40 price target, viewing the deal as strengthening the company's commercial portfolio after positive pipeline developments. The transaction is expected to close in the second half of 2026, according to Investing.com reports.
Sign in to access this content
Sign InThe acquisition comes amid heightened M&A activity in the biotech sector as companies seek to bolster product portfolios through strategic deals. YUPELRI, a once-daily nebulized bronchodilator, adds a new dimension to Zymeworks' portfolio, which currently focuses on oncology treatments. B. Riley emphasizes that the $40 price target reflects an attractive growth opportunity, particularly given potential sales and distribution synergies.
A specific trading price for Zymeworks shares was not available at the time of reporting, but analysts see the deal opening new avenues for growth. Investors await the progress of closing the transaction and securing regulatory approvals, as well as upcoming clinical trial results for the company's pipeline. The focus remains on Zymeworks' ability to integrate Theravance's operations and realize the expected returns from the new product.